{"result": "(\"entity\"<|>ADRENOLEUCODISTROFIA<|>EVENT<|>Adrenoleucodistrofia is a genetic disorder affecting lipid metabolism, characterized by late diagnosis and various neurological symptoms.)\n##\n(\"entity\"<|>BACLOFENO<|>ORGANIZATION<|>Baclofen is a medication used to treat spasticity associated with neurological disorders.)\n##\n(\"entity\"<|>VIGABATRINA<|>ORGANIZATION<|>Vigabatrin is a medication used for the treatment of epilepsy and spasticity.)\n##\n(\"entity\"<|>CARBAMACEPINA<|>ORGANIZATION<|>Carbamazepine is a medication used to treat seizures and neuropathic pain.)\n##\n(\"entity\"<|>FENOBARBITAL<|>ORGANIZATION<|>Phenobarbital is a barbiturate used to control seizures and as a sedative.)\n##\n(\"entity\"<|>BENZODIAZEPINAS<|>ORGANIZATION<|>Benzodiazepines are a class of medications used to treat anxiety, seizures, and insomnia.)\n##\n(\"entity\"<|>MITOCONDRIA<|>GEO<|>Mitochondria are organelles within cells that are responsible for energy production through lipid oxidation.)\n##\n(\"entity\"<|>PEROXISOMAS<|>GEO<|>Peroxisomes are organelles that play a role in lipid metabolism and the breakdown of fatty acids.)\n##\n(\"entity\"<|>ÁCIDOS GRASOS<|>EVENT<|>Fatty acids are important components of lipids and are involved in various metabolic processes.)\n##\n(\"entity\"<|>TRASTORNOS METABÓLICOS<|>EVENT<|>Metabolic disorders are conditions that disrupt normal metabolism, often affecting lipid and carbohydrate processing.)\n##\n(\"relationship\"<|>ADRENOLEUCODISTROFIA<|>BACLOFENO<|>Baclofen is used to treat spasticity, a symptom associated with Adrenoleucodistrofia<|>7)\n##\n(\"relationship\"<|>ADRENOLEUCODISTROFIA<|>VIGABATRINA<|>Vigabatrin is used to manage seizures, which can occur in patients with Adrenoleucodistrofia<|>7)\n##\n(\"relationship\"<|>ADRENOLEUCODISTROFIA<|>CARBAMACEPINA<|>Carbamazepine is used to treat seizures, a common issue in Adrenoleucodistrofia<|>7)\n##\n(\"relationship\"<|>ADRENOLEUCODISTROFIA<|>FENOBARBITAL<|>Phenobarbital is used for seizure control in patients with Adrenoleucodistrofia<|>7)\n##\n(\"relationship\"<|>ADRENOLEUCODISTROFIA<|>BENZODIAZEPINAS<|>Benzodiazepines may be used to manage anxiety and seizures in Adrenoleucodistrofia<|>6)\n##\n(\"relationship\"<|>BACLOFENO<|>ADRENOLEUCODISTROFIA<|>Baclofen is a treatment option for spasticity in Adrenoleucodistrofia<|>7)\n##\n(\"relationship\"<|>VIGABATRINA<|>ADRENOLEUCODISTROFIA<|>Vigabatrin is a treatment for seizures associated with Adrenoleucodistrofia<|>7)\n##\n(\"relationship\"<|>CARBAMACEPINA<|>ADRENOLEUCODISTROFIA<|>Carbamazepine is used to manage seizures in Adrenoleucodistrofia<|>7)\n##\n(\"relationship\"<|>FENOBARBITAL<|>ADRENOLEUCODISTROFIA<|>Phenobarbital is used for seizure management in Adrenoleucodistrofia<|>7)\n##\n(\"relationship\"<|>BENZODIAZEPINAS<|>ADRENOLEUCODISTROFIA<|>Benzodiazepines may be prescribed for anxiety and seizures in Adrenoleucodistrofia<|>6)\n##\n(\"relationship\"<|>MITOCONDRIA<|>ÁCIDOS GRASOS<|>Mitochondria are involved in the β-oxidation of fatty acids for energy production<|>8)\n##\n(\"relationship\"<|>PEROXISOMAS<|>ÁCIDOS GRASOS<|>Peroxisomes are involved in the metabolism of fatty acids, particularly in lipid disorders<|>8)\n##\n(\"relationship\"<|>TRASTORNOS METABÓLICOS<|>ADRENOLEUCODISTROFIA<|>Adrenoleucodistrofia is a type of metabolic disorder affecting lipid metabolism<|>9)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: inhibición de la sintasa del óxido nítrico y las\n---\n                              Tema 20.     Trastornos congénitos del metabolismo de los lípidos: Adrenoleucodistrofia…                      349\n\n\n\ncitoquinas proinflamatorias involucradas en la respues-                            Se caracterizan por su diagnóstico más tardío\nta inflamatoria cerebral. Se requieren estudios adicio-                            (> 2 años), y pueden debutar en forma de coma\nnales con mayor número de pacientes y con una mayor                                hipoglucémico, hepatopatía, enfermedad neuro-\nduración del tratamiento.                                                          lógica, aunque puede haber formas más tardías y\n   No debe olvidarse el tratamiento farmacológico de                               monosintomáticas.\nlas complicaciones de la enfermedad, como el trata-\nmiento de la espasticidad (baclofeno, vigabatrina), el                       2.2.   Dieta en los trastornos de la β-oxidación\ntratamiento de las crisis comiciales (carbamacepina,                                de los ácidos grasos de cadena larga\nfenobarbital, benzodiacepinas, etc. Y, por supuesto, el                             y muy larga\nestudio de la función suprarrenal es esencial para plan-\ntear el tratamiento esteroideo adecuado. La función                            La base del tratamiento dietético de estos trastornos\nsuprarrenal debe reevaluarse cada 4 meses.                                   consiste en31, 32:\nTerapia génica                                                                 1.  Evitar los períodos de ayuno:\n   La terapia génica se halla en fase de investigación, y                          Se recomiendan comidas frecuentes durante el\nhay diversas líneas en marcha. Se ha intentado incre-                              día (dependiendo de la edad y de los requeri-\nmentar la expresión de un gen funcionalmente relacio-                              mientos energéticos), y evitar al máximo un pe-\nnado con el gen X-ALD28, transferencia génica media-                               ríodo de ayuno prolongado durante la noche\nda por retrovirus, etc.                                                            (nunca más de 8 horas) Para ello, se aconseja un\n                                                                                   «resopón» a media noche que contenga almidón\n2.   Dietas controladas en ácidos grasos                                           crudo de maiz (maicena), otros hidratos de car-\n                                                                                   bono de absorción lenta, o en los casos graves\n2.1.   Introducción. Indicaciones de la dieta                                      con    afectación      neurológica,      nutrición    enteral\n   Las dietas controladas en ácidos grasos están indica-                           nocturna.\ndas en todos los trastornos metabólicos que afectan a                          2.  Restricción del aporte graso e incremento del\nla β-oxidación lipídica que tiene lugar en la mitocon-                             aporte de carbohidratos, con especial atención\ndria (AG de 20 o menos átomos de carbono), o en el                                 en mantener los requerimientos de ácidos grasos\ncaso de los AGCML, en los peroxisomas. La β-oxidación                              esenciales.\nlipídica es un proceso fundamental que aporta energía                              En los defectos de cadena larga se debe restringir\nen los períodos de ayuno (una vez el glucógeno hepá-                               la cantidad de grasa total a menos del 30% del\ntico ya se ha deplecionado) y de estrés. El corazón, el                            valor calórico total de la dieta, y además menos\nhígado y el músculo esquelético son especialmente de-                              del 10% de la energía debe ser en forma de trigli-\npendientes de esta vía metabólica.                                                 céridos de cadena larga (TCL) Una restricción ma-\n   Los trastornos de la β-oxidación de los ácidos gra-                             yor comportaría riesgos de déficit de ácidos gra-\nsos son metabolopatías que se heredan de forma auto-                               sos esenciales. Los AGCL y AGCML pueden ser\nsómica recesiva, y que en su mayor parte se caracteri-                             sustituidos     por   triglicéridos    de   cadena     media\nzan por hipoglucemia no cetósica, con mala tolerancia                              (TCM), que no requieren del sistema de la carni-\na los períodos de ayuno. Otros síntomas que pueden                                 tina para entrar en la mitocondria y son oxidados\nacompañar a estos trastornos metabólicos son mio-                                  eficazmente, a la vez que suprimen la oxidación\npatía, hepatopatía, y en ocasiones neuropatía y arrit-                             de los AGCL. La cantidad de TCM a administrar\nmias cardiacas29,30 . El espectro clínico y la gravedad                            es de aproximadamente un 10-20 % del total de\ndifieren según el déficit enzimático y la edad de de-                              las calorías de la dieta.\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}